Shinohara, Keisuke
Ikeda, Shota
Enzan, Nobuyuki
Matsushima, Shouji
Tohyama, Takeshi
Funakoshi, Kouta
Kishimoto, Junji
Itoh, Hiroshi
Komuro, Issei
Tsutsui, Hiroyuki
Article History
Received: 20 April 2021
Revised: 6 July 2021
Accepted: 25 July 2021
First Online: 15 September 2021
Compliance with ethical standards
:
: KS reports grants from Daiichi Sankyo and Nippon Boehringer Ingelheim. HI reports grants and/or personal fees from Shionogi, Takeda Pharmaceutical, Nippon Boehringer Ingelheim, Daiichi Sankyo, MSD, Mitsubishi Tanabe Pharma, Sumitomo Dainippon Pharma, Astellas Pharma, Kyowa Kirin, Ono Pharmaceutical, Chugai Pharmaceutical, Novartis Pharma, Kao, Mochida Pharmaceutical, Oriental Yeast, Abbott Japan, Bayer Yakuhin, LifeScan Japan, SBI Pharmaceuticals, Nipro, and Wakunaga Pharmaceutical. IK reports grants and/or personal fees from Takeda Pharmaceutical, Nippon Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, MSD, Mitsubishi Tanabe Pharma, Bristol-Myers Squibb, Ono Pharmaceutical, AstraZeneca, Novartis Pharma, Bayer Yakuhin, Pfizer Japan, Idorsia Pharmaceuticals Japan, and Teijin Pharma. HT reports grants and/or personal fees from Daiichi Sankyo, Novartis Pharma, Otsuka Pharmaceutical, Pfizer Japan, Mitsubishi Tanabe Pharma, Teijin Pharma, Nippon Boehringer Ingelheim, Bayer Yakuhin, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Kowa, Japan Tobacco, IQVIA Service Japan, Omron Healthcare, MEDINET, Medical Innovation Kyushu, Abbott Medical Japan, Teijin Home Healthcare, and Boston Scientific Japan. The other authors report no competing interests.